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ABSTRACT
HER-2 (ErbB-2, c-erbB2 or Her2/neu), a member of the HER-family, is directly 
involved in the pathogenesis and progression of several human cancers; as such, it is 
also often considered as a poor prognostic factor. Following the revolutionary impact 
of anti-HER-2 therapy in breast cancer patients, the role of HER-2 and its blockade has 
also been extensively evaluated in other tumor types, including gastric and colorectal 
adenocarcinoma. The aims of this review are to recall the important results achieved 
with the use of HER-2 inhibitors in both gastric and colorectal cancer, and to discuss 
on the updates available on the role of HER-2 as prognostic and predictive factor in 
these malignancies.
INTRODUCTION
HER-2 (ErbB-2, c-erbB2 or Her2/neu), a member 
of the HER-family that also includes HER-1 (Epidermal 
Growth Factor Receptor-EGFR, or ErbB1), HER-3 
(ErbB3) and HER-4 (ErbB4), is a proto-oncogene that 
encodes for a 185-kDa plasma membrane-bound tyrosine 
kinase receptor, located on the chromosome 17 at q21 
[1]. Its stimulation by extracellular signals leads to the 
activation of downstream pathways such as mitogen-
activated protein kinase (MAPK), phosphoinositide-
3-kinase (PI3K), phospholipase C and protein kinase 
C, inducing signal transduction and transcription [2, 
3]. As such, HER-2 gene amplification and protein 
overexpression are involved in the pathogenesis and 
progression of several human cancers, thus they are often 
considered as a poor prognostic factor [4-6]. HER-2/
neu overexpression has been reported in many epithelial 
malignancies including lung, prostate, bladder, pancreatic 
cancer and osteosarcoma. But it is mainly due to the 
                  Review
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revolutionary impact of anti-HER-2 therapy in breast 
cancer patients that the role of HER-2 and its blockade 
has been evaluated also in other tumor types, including 
gastric and colorectal cancers (CRC). Although several 
targeted agents have been tested in randomized trials [7, 
8], only trastuzumab in HER2-positive patients [9] and 
ramucirumab in an unselected population [10, 11] are 
currently approved in gastric cancer. Similarly to gastric 
cancer, also CRC is a highly heterogeneous disease [12-
14]. In such novel and more complex scenario, a better 
definition of HER-2 function in CRC has been achieved 
suggesting its involvement in disease pathogenesis as well 
as in the emergence of resistance to target therapy [15, 
16]: as a result, HER-2 has been regarded as a potential 
therapeutic target.
The aims of this review are to recall the important 
results achieved with the use of HER-2 inhibitors in gastric 
and gastroesophageal junction cancers (as illustrated 
in Figure 1), and to discuss the updates on the role of 
HER-2 as prognostic and predictive factor in gastric and 
colorectal carcinomas.
HER-2 AS A KEY TARGET IN GASTRIC 
CANCERS AND GASTROESOPHAGEAL 
JUNCTION CARCINOMAS
Gastric cancer is a worldwide health problem, 
causing approximately one million deaths per year and 
ranking as the third leading cause of cancer-related deaths 
[17, 18]. Although the role of HER-2 in this tumor has 
Figure 1: Mechanisms of actions of HER-2 inhibitors. The figure shows the complex crosstalk between members of the HER-
family and intracellular signaling, involved in proliferation, growth, invasion/metastases and angiogenesis. Activation of receptor kinase 
function occurs predominantly via ligand-mediated hetero- or homo-dimerization. In the case of HER-2, activation is also thought to occur 
in a ligand-independent manner, particularly when the receptor is found to be mutated or overexpressed. Trastuzumab is directed against 
the extracellular domain (IV) of HER-2, while pertuzumab binds to the extracellular dimerization domain (subdomain II). Immunologic 
mechanisms may also be involved in antitumor activity of trastuzumab, pertuzumab, and TDM-1, including ADCC. The potent small-
molecule lapatinib inhibits the tyrosine kinases associated with HER-1 and HER-2, resulting in inhibition of phosphorylation and 
downstream signaling. ADCC: antibody-dependent cell-mediated cytotoxicity, HER: human epidermal growth factor receptor, MAPK: 
mitogen-activated protein kinase, MAPKK: mitogen-activated protein kinase kinase, mTOR: mammalian target of rapamycin, P: phosphate 
group, PI3K: phosphatidylinositol 3-kinase, PKC: protein kinase C, PLCγ: phospholipase C-gamma, TDM-1: trastuzumab emtansine.
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already been extensively investigated [19], and found to 
be frequently associated with invasion, high grade, and 
unfavorable prognosis, its overall prognostic role remains 
controversial [20-24] and appears to be stage-dependent.
HER-2 positivity in gastric cancer is usually 
established with immunohistochemistry (IHC) and further 
confirmed with in situ hybridization (ISH) methods. 
Currently, tumor scoring slightly diverges between small 
endoscopic biopsies and surgical specimens (see Table 1 
for details). ISH analysis, either with fluorescence in situ 
hybridization (FISH) or chromogenic in situ hybridization 
(CISH), is required for tumors with an IHC score 2+ for 
which further assessments are needed to define the HER-
2 status [25, 26]. Of note, HER-2 positivity may vary 
depending on the primary tumor location as well as the 
histology of gastric cancer. As a matter of fact, HER-2 
overexpression/amplification is detected in more than 
30% of the tumors arising from the gastroesophageal 
junction whereas less than 20% of the tumors arising from 
the gastric body are HER2-positive. Likewise, intestinal 
histology and diffuse histotype display a rate of HER-2 
positivity of 34% and 6%, respectively [27]. The Cancer 
Genome Atlas project has identified four subtypes of 
gastric cancer based on their different molecular biology, 
which could actually explain such variability in HER-2 
expression [28].
The relevant biological role played by HER-2 
eventually led to explore its potential as a therapeutic 
target. ToGA, a large international randomized phase 
III study, investigated the efficacy and safety of adding 
trastuzumab to combination chemotherapy of a 
fluoropyrimidine (capecitabine or 5-FU) plus cisplatin for 
the upfront treatment of HER2-positive advanced gastric 
cancer patients [9]. The study enrolled 594 patients in 
24 countries. This practice-changing study showed that 
the addition of trastuzumab to backbone chemotherapy 
significantly prolonged the median overall survival 
(OS) compared with chemotherapy alone (13.8 months 
vs. 11.1 months, HR 0.74, 95%CI 0.60-0.91); of note, a 
post-hoc analysis showed that the overall survival gain 
was even greater (+4.2 months, HR 0.65) for patients 
with higher HER-2 expression, i.e., IHC HER-2 3+ 
score or IHC HER-2 2+ score and amplified FISH (16.0 
months vs. 11.8 months, HR 0.65, 95%CI 0.51-0.83) 
[9]. Full screening results from the ToGA study have 
been recently reported, including data on IHC and FISH 
testing. A total of 3,803 patients were screened for HER-
2 status; either IHC or FISH testing was successful in 
3,665 patients. Concordance between the two methods 
was 87.2%; HER-2 overexpression/amplification rates 
were similar for European and Asian patients, but 
slightly lower for American patients. As previously 
reported, HER-2 overexpression or amplification was 
more common in patients with intestinal histology 
compared with those with diffuse histology (31.8 % vs. 
6.1%) and in gastroesophageal junction cancer than in 
gastric cancer (32.2% vs. 21.4%), suggesting a different 
etiology and pathogenesis between proximal and distal 
gastric cancers [29]. However, a critical factor for the 
selection of potential responders to a trastuzumab-based 
Table 1: Currently used HER-2 immunohistochemistry scoring system in gastric cancer depends on the available 
specimen.
SCORE 
TO 
REPORT
HER-2 RECEPTOR
OVEREXPRESSION
ASSESSMENT
SCORING PATTERN:
SURGICAL SPECIMEN
SCORING PATTERN:
SMALL ENDOSCOPIC BIOPSIES
(AT LEAST 6-8 DIAGNOSTIC 
FRAGMENTS)
0 Negative No reactivity or membranous reactivity in <10% of tumor cells No reactivity in any tumor cell
1+ Negative
Faint/barely perceptible incomplete 
membranous reactivity in ≥10% of 
tumor cells
Tumor cell cluster with a faint/barely 
perceptible incomplete membranous reactivity 
irrespective of percentage of tumor cells 
stained
2+ Equivocal
Weak to moderate complete, 
basolateral or lateral membranous 
reactivity in ≥10% of tumor cells
Tumor cell cluster with a weak to moderate 
complete, basolateral or lateral membranous 
reactivity irrespective of percentage of tumor 
cells stained
3+ Positive
Strong complete, basolateral or 
lateral membranous reactivity in 
≥10% of tumorcells
Tumor cell cluster with a strong complete, 
basolateral or lateral membranous reactivity 
irrespective of percentage of tumor cells 
stained
HER-2: human epidermal growth factor receptor 2.
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therapy remains the intratumoral heterogeneity of HER-
2 amplification [30, 31] which, together with a lack of 
uniformity and reproducibility of the criteria used for 
defining HER-2 positivity, could be responsible for 
the variable incidence rates reported in literature [32]. 
Following the positive results of ToGA trial, further 
investigations have been conducted in order to: a) define 
the optimal dose of trastuzumab in combination with 
chemotherapy; b) extend the addition of trastuzumab to 
other disease settings (i.e. preoperative or perioperative) 
and c) test the efficacy of novel HER-2 inhibitors either 
alone or in combination with trastuzumab.
The identification of the most appropriate dose of 
trastuzumab in addition to chemotherapy is currently being 
pursued within the HELOISE trial, a randomized phase 
III study, which compares two different dosing regimens 
(loading dose of 8 mg/kg followed by either 6 mg/kg or 10 
mg/kg of trastuzumab given every 3 weeks) in association 
with cisplatin/capecitabine chemotherapy, as first-line 
therapy in patients with HER2-positive metastatic gastric 
or gastro-esophageal junction adenocarcinoma. Primary 
study endpoints are safety and tolerability of an alternative 
trastuzumab dosing regimen based on a post-hoc analysis 
of ToGA trial [33]. In this trial, eligible patients have poor 
prognostic factors as ECOG performance status 2, primary 
tumor in site and metastatic involvement of at least two 
organs. In ToGA trial, trastuzumab was administered 
with an initial loading dose of 8 mg/kg followed by a 
maintenance dose of 6 mg/kg every 3 weeks. A total 
of 1,419 serum concentrations from 266 patients had 
a non-linear two-compartment pharmacokinetics (PK) 
with parallel linear and non-linear elimination. The non-
linear elimination pathway of trastuzumab is believed to 
represent a target-mediated clearance process associated 
with the binding to the extracellular domain of the HER-2 
protein. For the dosing regimen investigated in the study, 
the non-linear pathway was not saturated continuously, 
leading to a change in the overall trastuzumab clearance 
between consecutive infusions. Based on the predicted 
concentrations, the total clearance was stable within 
the first 3 days but increases by 48% as concentrations 
decline. A post-hoc Kaplan Meier survival analysis was 
conducted with patients stratified according to quartile of 
trastuzumab trough concentration in treatment at cycle 1. A 
significant difference in survival was observed according 
to quartile of trough trastuzumab concentrations in cycle 
1 (p  < 0.0001). Median survival time for patients within 
the lowest quartile of concentrations was 7.7 months (95% 
CI 6.3-10.6 months), which was 7 to 10 months shorter 
than median survival time reported for patients with 
trough concentrations within other quartiles [34]. Whether 
the addition of trastuzumab is beneficial also in settings 
other than metastatic has also been investigated in a 
number of studies which, as a matter of fact, have already 
shown favorable outcomes of trastuzumab-containing 
perioperative chemotherapy. In the explorative HERFLOT 
phase II study, the activity of trastuzumab in addition 
to perioperative FLOT (5-FU, leucovorin, oxaliplatin 
and docetaxel) is being evaluated. The primary study 
endpoint is the rate of pathological complete response 
(pCR) evaluated by a central reference pathologist. 
Preliminary data presented on an interim analysis 
revealed no unexpected safety issues and a pCR achieved 
in more than 20% patients. Final results are awaited 
later this year [35]. Similarly, the PETRARCA phase II/
III trial of the AIO Group is evaluating the addition of 
trastuzumab and pertuzumab to FLOT vs FLOT alone in 
perioperative setting [36]. Moreover, the INNOVATION 
phase II study is assessing the activity of trastuzumab or 
trastuzumab plus pertuzumab in addition to perioperative 
standard chemotherapy [37]. In the TOXAG phase II trial, 
safety and tolerability of oxaliplatin, capecitabine and 
trastuzumab combination and radiotherapy as adjuvant 
therapy in surgically resected HER2-positive gastric or 
gastroesophageal junction cancer are being evaluated 
[38]. Finally, RTOG 1010 phase III is enrolling patients 
with esophageal HER2-positive adenocarcinoma in 
order to establish the efficacy of adding trastuzumab to 
chemoradiation [39]. 
Meanwhile, novel HER-2 inhibitors are also being 
studied in gastric cancer: lapatinib ditosylate, a dual anti-
EGFR and anti-HER-2 tyrosine kinase inhibitor, was 
firstly tested in the TRIO-013/LOGiC trial designed to 
evaluate the efficacy and safety of the oral inhibitor in 
combination with capecitabine and oxaliplatin as first-
line treatment of advanced or metastatic HER2-positive 
esophagogastric cancer. In this study, 545 patients were 
randomized 1:1 to receive CAPOX q21 (oxaliplatin 130 
mg/sqm, day 1, capecitabine 850 mg/sqm/bid days 1-14) 
plus lapatinib (1,250 mg daily given continuously) or 
placebo. The primary endpoint was not met with an HR 
for OS of 0.91 (95% CI 0.73-1.12; p = 0.35), and a median 
OS of 12.2 months for standard treatment vs. 10.5 months 
in the experimental arm. Median progression-free survival 
(PFS) was 6.0 months (95% CI, 5.6 to 7.0) in experimental 
arm and 5.4 months (95% CI, 4.4 to 5.7) in control arm 
with an HR of 0.82 (95% CI,0.68-1.00; p = 0.0381). 
Overall Response Rate (ORR) was 53% (95% CI, 46.4-
58.8) in the experimental arm and 39% (95% CI, 32.9-
45.3, p = 0.0031) in the placebo arm [40]. In the open-
label, phase III TyTAN trial, 261 HER2-positive advanced 
gastric cancer Asian patients were randomized to receive 
weekly paclitaxel with or without lapatinib, as second-
line treatment. Once again, no benefit was demonstrated 
in terms of OS (HR 0.84, 95% CI 0.64-1.11; p = 0.10) or 
PFS (HR 0.85, 95%CI 0.63-1.13; p  = 0.24) for the use of 
lapatinib, though a statistically significant improvement in 
RR was noted (27% v 9%, OR 3.85, 95%CI 1.80-8.87; p 
= 0.001) [41].
Possible reasons for these negative results are the 
high proportion of patients with IHC HER-2 1+ score, 
which might have diluted the benefit of lapatinib in patients 
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with IHC HER-2 3+ score, as well as the different rate 
of potentially active third-line treatments between study 
arms. Moreover, in TRIO-013/LOGiC trial, no correlation 
was observed between IHC status and OS benefit. Despite 
these uncertainties, lapatinib was not approved for gastric 
cancer. Key results of the most important randomized 
trials are summarized in Table 2. Ongoing studies 
might better define its role in combination with other 
targeted agents. Pertuzumab, a recombinant, humanized 
immunoglobulin IgG1κ monoclonal antibody which 
binds to the extracellular domain of HER-2 preventing 
its heterodimerization with other members of the HER-
family (HER-1, HER-3, and HER-4), has been studied 
to overcome trastuzumab resistance. Pertuzumab and 
trastuzumab bind to distinct epitopes of HER-2 without 
competing with each other and have complementary 
mechanisms of HER-2 signaling disruption, resulting 
in synergistic antiproliferative activity both in vitro and 
in vivo. Based on the promising results from preclinical 
trials [42], the encouraging activity reported in early 
clinical trials enrolling gastric cancer patients [43], and 
the great efficacy of the combination of trastuzumab and 
pertuzumab in breast cancer [44], the phase III JACOB 
trial (BO 25114) was designed to assess whether the 
addition of pertuzumab to cisplatin, 5-Fluorouracil and 
trastuzumab may further improve the survival of HER2- 
positive gastric cancer patients with an acceptable safety 
profile [45]. Investigators reached the recruitment target 
of 780 patients enrolled in the JACOB study on January 
2016 and results from this important trial are eagerly 
awaited. Moreover, an ongoing randomized phase IIa 
study is enrolling previously untreated advanced gastric 
cancer patients to better characterize the pharmacokinetics 
and safety of pertuzumab [43]. Novel strategies to target 
HER-2 include the combination of cytotoxic agents and 
antibodies with high activity like trastuzumab emtansine 
(TDM-1). This antibody, specifically designed to deliver 
an antiproliferative agent to HER-2 overexpressing 
cancer cells, conjugates the targeted anti-HER-2 activity 
of trastuzumab with the intracellular cytotoxic effect 
of emtansine, a tubulin polymerase inhibitor [46]. In a 
multicenter, randomized Phase II/III study the efficacy 
and safety of TDM-1 was compared to standard taxane 
treatment in patients with HER2-positive pretreated 
advanced gastric cancer. Participants were randomized 
to receive either trastuzumab emtansine 3.6 mg/kg every 
3 weeks or trastuzumab emtansine 2.4 mg/kg every 
week or single-agent taxane (docetaxel or paclitaxel as 
per investigator choice). The aim of the first phase of 
the study was to choose the optimal TDM-1 dose and 
schedule. Despite better safety profile of TDM-1, accrual 
has been prematurely discontinued for failure of primary 
Table 2: Principal results with HER-2 inhibitors in advanced HER2-positive gastric cancer.
TRIAL REGIMEN PHASE LINE PRIMARY ENDPOINT ORR (%)
PFS 
(months)
OS 
(months)
Experimental 
Arm Control Arm
ToGA
NCT01041404
Capecitabine 
or iv 5-FU
+
Cisplatin
+
Trastuzumab
Capecitabine 
or iv 5-FU
+
Cisplatin
III I OS
47.3 vs. 34.5
OR = 1.70,
95% CI 
1.22 – 2.38,
p = 0.0017
6.7 vs. 5.5
HR = 0.71,
95% CI 
0.59-0.85,
p = 0.0002
13.8 vs. 
11.1
HR = 0.74,
95% CI 
0.60-0.91,
p = 0.0046
LOGiC
NCT00680901
Capecitabine + 
Oxaliplatin + 
Lapatinib
Capecitabine 
+ Oxaliplatin 
+ Placebo
III I OS
53 
(95% CI 46.6-
59.3)
vs.
40 
(95% CI 33.6-
46.4)
6.0 vs. 5.4
HR = 0.86,
95% CI 
0.71-1.04,
p = 0.10
12.2 vs. 
10.5
HR = 0.91,
95% CI 
0.73-1.12,
p = 0.3492
TyTAN
NCT00486954
Paclitaxel + 
Lapatinib
Paclitaxel + 
Placebo III II OS
27 vs. 9
OR = 3.85,
95% CI 
1.80-8.87,
p < 0.001
5.4 vs. 4.4
HR = 0.85,
95% CI 
0.63-1.13,
p = 0.2441
11.0 vs. 8.9
HR = 0.84,
95% CI 
0.64-1.11,
p = 0.2088
GATSBY
NCT01641939
TDM-1 
3.6 mg/kg q21
or
TDM-1 
2.4 mg/kg q7
Paclitaxel or 
Docetaxel II/III II OS 20.6 vs 19.6
2.7 vs 2.9
HR=1.13,
95% CI
0.89-1.43,
p = 0.31
7.9 vs 8.6
HR= 1.15,
95% CI
0.87-1.51,
p = 0.86 
5-FU: 5-fluorouracil, CI: confidence interval, HR: hazard ratio, OR: odds ratio, iv: intravenous, ORR: overall response rate, 
OS: overall survival, PFS: progression-free survival, TDM-1: trastuzumab emtansine.
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endpoint at first interim analysis [47]. Although a number 
of molecular mechanisms underpinning resistance to 
trastuzumab-based therapies have been already identified, 
a thorough investigation of such mechanisms will help 
clinicians to appropriately design future trials [8, 48].
One of the possible mechanisms associated with 
trastuzumab resistance is the deregulation of HER-2 
downstream signal, including the PI3K/AKT/mTOR 
pathway. It is well known that PIK3CA mutations and 
PTEN inactivation result in constitutive activation of 
the downstream signals [49]. Everolimus, an orally 
administered mTOR inhibitor, showed enhanced 5-FU-
induced apoptosis in gastric cancer cells with HER-2 
amplification and promising activity in preclinical and 
early clinical trials [50, 51]: such results, however, have 
not been confirmed in the phase III GRANITE-1 trial. 
[52]. It is uncertain whether the combination of HER2-
targeted agents and mTOR inhibitors might provide 
benefit in patients with HER2-positive gastric cancer 
who became resistant: the identification of predictive 
biomarkers remains crucial for optimizing efficacy.
Afatinib, an oral irreversible inhibitor of tyrosine 
kinase receptors targeting HER-1, HER-2 and HER-4, 
may help overcoming trastuzumab resistance. Preliminary 
data of a phase II study enrolling patients with metastatic 
HER2-positive (IHC 3+ or FISH >2.0) esophagogastric 
cancer with disease progression whilst on a trastuzumab-
containing regimen have been recently presented [53, 54] 
with demonstration of a 40% disease control.
As pan-HER inhibitors have shown significant 
antitumor effects in vitro as well as in xenograft model of 
HER2-positive gastric cancer [55], the efficacy and safety 
of dacomitinib, an irreversible pan-HER tyrosine kinase 
inhibitor, was investigated in advanced gastric cancer 
patients. Twenty-seven pretreated gastric cancer patients 
received dacomitinib 45 mg once daily continuously every 
4 weeks. The 4-months PFS rate, the primary endpoint of 
the study, was 22.2% and median PFS was 2.1 months 
(95% CI 2.3-3.4). Disease control rate was 40.7% (95% 
CI 21.9-59.6%). Median OS was 7.1 months (95% CI 4.4-
9.8). The most common adverse events were skin rash, 
diarrhea, and fatigue, while no treatment-related deaths 
were seen [56].
Moreover, data suggest that HER-3 might play a key 
role in tumorigenesis and act as a mediator of resistance to 
HER-2 inhibitors. MM-111, a novel molecule that inhibits 
heregulin-activated HER-3 signaling, has been shown to 
mitigate HER3-mediated resistance in preclinical gastric 
Table 3: Principal ongoing trials in neoadjuvant HER2-positive gastric or gastroesophageal cancer.
TRIAL REGIMEN PHASE PRIMARY ENDPOINT
Experimental Arm Control Arm
HERFLOT
NCT01472029
5-FU
+ Leucovorin
+ Oxaliplatin
+ Docetaxel
+ Trastuzumab 6 mg/kg iv loading 
dose, followed by 4 mg/kg iv every 
2 weeks
5-FU
+ Leucovorin
+ Oxaliplatin
+ Docetaxel
II pCR
PETRARCA
NCT02581462
5-FU
+ Leucovorin
+ Oxaliplatin
+ Docetaxel
+ Trastuzumab 8 mg/kg iv loading 
dose, followed by 6 mg/kg iv every 
3 weeks
+Pertuzumab  840 mg every 3 weeks
5-FU
+ Leucovorin
+ Oxaliplatin
+ Docetaxel
II/III pCR/PFS
INNOVATION
NCT02205047
5-FU/Capecitabine
+ Cisplatin
+ Trastuzumab/Pertuzumab
5-FU/Capecitabine
+ Cisplatin II pCR
TOXAG
NCT01748773
RT at Total dose of 45 Gy divided 
into 25 doses
+Capecitabine
+ Oxaliplatin
+ Trastuzumab 8 mg/kg iv loading 
dose, followed by 6 mg/kg iv every 
3 weeks
// II Safety
RTOG 1010
NCT01196390
RT
+ Paclitaxel
+ Carboplatin
+ Trastuzumab
RT
+ Paclitaxel
+ Carboplatin III DFS
5-FU: 5-fluorouracil, OS: overall survival, PFS: progression-free survival, RT: radiotherapy, iv: intravenous, pCR: pathological 
complete response, DFS: disease free survival.
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models [57]; thus, it is being tested within different 
trials in order to assess whether its addition might lead 
to an increased antitumor activity of trastuzumab and 
paclitaxel. [58]. Recent advances in HER-2 biology have 
expanded the use of HER-2 inhibitors in gastric cancer 
patients. Nevertheless, the underpinning molecular 
mechanisms of gastric cancer progression as well as 
the strategies to overcome resistance need to be further 
elucidated. International collaborative efforts to improve 
the knowledge on the background biology of this disease 
are ongoing (Table 3 and Table 4), as well as clinical and 
translational studies testing other novel HER-2 inhibitors.
HER-2: A NOVEL POTENTIAL TARGET IN 
COLORECTAL CANCER
In Western countries, CRC is one of the most 
common malignancies being the second leading cause of 
cancer-related death in the United States [17]. Despite the 
treatment advances achieved so far, with OS overcoming 
30 months in genetically selected patients, metastatic CRC 
remains an incurable disease [59-62]. It is worth noting 
that, although most of the patients who have exhausted 
all standard treatments usually have a limited survival 
[63, 64], some of them may still have a good performance 
status and strongly desire further treatment. Paramount 
discoveries about the molecular biology underpinning 
CRC have been made [65], but we are still far from a 
thorough understanding of the tumor biology and the role 
of HER-2 overexpression and amplification in CRC.
HER-2 protein is usually weakly expressed in 
the membrane and/or cytoplasm of colonic epithelium, 
whereas the membrane of tumor cells may have various 
staining patterns [66].
The incidence of HER-2 expression in colon 
adenocarcinoma ranges from 0% to 83% [67-69] and 
reports on HER-2 gene amplification and HER-2 
overexpression in metastatic CRC have been discordant. 
It is commonly agreed that such wide range may reflect 
differences in technical approaches, antibodies used, 
and scoring protocols, as well as study biases associated 
with patient selection [70, 71]. Most of the studies 
showed membranous overexpression rates between 0 
and 15%. Of note, some studies reported higher rates 
of both membranous and cytoplasmic overexpression, 
up to 60%. Major hurdles in comparing HER-2 IHC 
studies in CRC are the variety of antibodies used as well 
as how technical issues are differently handled across 
protocols such as tissue fixation, slide storage procedures, 
antigen retrieval, and incubation time. To overcome such 
problems, a standard and reproducible staining procedure 
is highly needed. Overall, about 5% of CRC have HER-
2 membranous overexpression, far lower than what it is 
observed in breast cancer [72, 73], while the cytoplasmic 
overexpression varies strongly with an average of 30%. 
However, it is likely that this value is underestimated due 
to the loss of HER-2 antigen in older tissue samples [74].
The disagreement in evaluating HER-2 expression 
at every level (nuclear, cytoplasmic and cell surface) 
emphasizes the limitations of using IHC evaluation alone 
and points out the need for further predictive biomarkers 
for HER2-targeted therapies in tumors displaying 
overexpression in gene copy number, mRNA and receptor 
protein [71].
Several studies analyzed HER-2 overexpression 
in CRC with genomic techniques such as fluorescence 
in situ hybridization (FISH), reverse transcription 
polymerase chain reaction (RT-PCR), Southern blotting, 
and Northern blotting. Altogether, these results confirmed 
that IHC 3+ overexpression is conclusive for gene 
amplification, whereas 2+ staining may be equivocal 
and likely associated with other mechanisms of genetic 
overexpression [74].
In a retrospective study, Tu et al. described a 
consistency between the levels of HER-2 protein 
expression determined by IHC and HER-2 gene 
Table 4: Principal ongoing trials in advanced HER2-positive gastric cancer.
TRIAL REGIMEN PHASE LINE PRIMARY ENDPOINT
Experimental Arm Control Arm
HELOISE
NCT01450696
Capecitabine
+ Cisplatin
+ Trastuzumab 8 mg/kg iv loading dose, 
followed 10 mg/kg iv every 3 weeks
Capecitabine
+ Cisplatin
+ Trastuzumab 8 mg/kg iv loading dose, 
followed by 6 mg/kg iv every 3 weeks
III I OS
JACOB
NCT01774786
Capecitabine/5-FU
+ Cisplatin
+ Trastuzumab
+ Pertuzumab
Capecitabine/5-FU
+ Cisplatin
+ Trastuzumab
+ Placebo
III I OS
NCT01774851
Paclitaxel
+ Trastuzumab
+ MM-111
Paclitaxel
+ Trastuzumab II II PFS
5-FU: 5-fluorouracil, OS: overall survival, PFS: progression-free survival. iv: intravenous
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amplification determined by FISH in 102 HER-2 
overexpressed CRC samples. A relatively high level 
of consistency was observed between IHC 0/1+/3+ 
with FISH (24.5% of the IHC 3+ cases showed HER-
2 gene amplification by FISH and none of the 20 
randomly selected IHC 0/1+ cases demonstrated FISH 
amplification); however, there was a low level of 
consistency between IHC 2+ results and FISH. Of note, 
no association between HER-2 overexpression or gene 
amplification and survivorship was seen. [75]
In CRC, the clinical significance of HER-2 is 
still controversial. While some data seem to link HER-
2 overexpression to decreased survival, suggesting that 
HER-2 may be a potential negative prognostic factor, other 
studies failed to confirm similar results [74]. Additionally, 
it is unclear whether HER-2 may be exploited as a 
potential therapeutic target in CRC patients [67].
CRC is a highly heterogeneous disease meaning, 
from a practical point of view, that some of the cellular 
clones will be sensitive to specific therapies while others 
will be not. Moreover, this heterogeneity dynamically 
varies under treatment pressure: while sensible clones 
start to disappear, resistant clones may eventually 
emerge and expand leading to disease progression. At 
this point, a new treatment may overcome resistance to 
previous compounds, determining another cancer clone 
remodeling [12-14]. As such, the selection of patients for 
a specific treatment is fundamental and, when available, 
predictive factors to both response and resistance are to be 
considered. Cetuximab and panitumumab, two epidermal 
growth factor receptor (EGFR) inhibitors approved for 
the treatment of metastatic CRC, are a stark example 
of this. KRAS, NRAS, BRAF, and possibly PIK3CA 
mutations prevent the efficacy of these drugs, confirming 
that constitutive activation of parallel or downstream 
pathways may bypass EGFR inhibition. Since EGFR may 
also heterodimerize with other members of HER family, it 
is reasonable to consider HER-2 as an additional response 
predictor [16].
In truth, HER-2 amplification seems to be associated 
with KRAS wild-type tumors and may cause acquired 
resistance to EGFR inhibition [15]. In the largest case 
series ever published, including tissue samples of 1,645 
primary CRC patients, HER-2 status was assessed by IHC 
using the monoclonal antibody SP3. IHC 3+ score were 
reported as positive, 2+ score as equivocal, and 0/1+score 
as negative. Tumors scoring 2+ were further evaluated 
by CISH to assess HER-2 amplification. Only 9 cases 
were upfront scored as HER2-positive, while 35 cases 
showed an equivocal result. All cases scored 2+ and 3+, 
and 54 randomly selected 0/1+ cases were additionally 
tested on whole tissue sections. Overall, 1.6% of the 
whole CRC cohort was HER2-positive (26 out of 1,645). 
No differences between HER-2 status on primary tissue 
sample and resected locoregional nodes were reported. 
HER-2 positivity significantly correlated with higher stage 
at diagnosis and with the presence of nodal metastasis. 
Although not statistically significant, the rate of HER-
2 positivity was higher in rectal than in colon cancers. 
Despite a trend toward worse prognosis, HER2-positivity 
had no significant impact on survival [76]. In line with 
these results, other recent series including a smaller 
number of patients have confirmed a similar low rate of 
HER-2 positivity in patients with CRC [66, 77] or rectal 
cancer [78].
In order to explore whether HER-2 was 
overexpressed and/or amplified in tumors from patients 
resistant to anti-EGFR antibodies, Bertotti et al. used 
direct transfer xenografts as a new strategy to anticipate 
clinical findings and to possibly optimize tailored 
treatment for these patients. For each tumor specimen, 
some fragments were subcutaneously implanted in 
immunodeficient mice and then expanded to generate 
a pair of independent xenograft lines for each patient 
(xenopatients). HER-2 amplification/overexpression was 
reported only in KRAS wild-type tumors that progressed 
on cetuximab or panitumumab [15], suggesting that HER-
2 amplification may limit EGFR-inhibitors activity in RAS 
wild-type tumors.
Whether HER-2 gene copy number status may 
influence the response to cetuximab or panitumumab 
has also been retrospectively assessed in a large cohort 
of patients, who were divided into three groups according 
to their FISH evaluation. The results of this analysis 
showed that HER-2 amplification was associated with 
EGFR-inhibitors resistance and affected both PFS and 
OS [16]. Such findings support the results by Bertotti et 
al. and those by Yonesaka et al., who highlighted how 
the activation of ERBB2 signaling causes resistance to 
cetuximab leading to a worse prognosis [79].
The potential role of HER-2 in inducing resistance 
in CRC cells exposed to EGFR-inhibitors, was further 
investigated in a preclinical study where the impact 
of somatic mutations by introducing the HER2 V842I 
mutation, the most prevalent HER-2 mutation identified 
in CRC samples according to the Cancer Genome Atlas 
[80], into the cetuximab-sensitive colorectal cell line DiFi 
was assessed. The introduction of the V842I mutation 
caused a 40- to 100-fold shift in the half maximal 
inhibitory concentration (IC50) values of both cetuximab 
and panitumumab. Moreover, the impact of five HER-2 
mutations in another cetuximab-sensitive CRC cell line 
(NCI-H508) was explored showing that all mutations led 
to the emergence of EGFR-inhibitors resistance. Western 
blots of the EGFR-HER2 signaling pathways suggested 
that the mechanism of anti-EGFR resistance consisted in 
sustaining MAPK phosphorylation. Based on preclinical 
studies, which showed that HER-2 mutations can be 
strongly inhibited by nanomolar doses of neratinib or 
afatinib [81, 82], both irreversible HER2/EGFR tyrosine 
kinase inhibitors were tested on DiFi and NCI-H508 cells 
transduced with HER-2 mutations leading to growth 
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inhibition. Moreover, the authors sequenced the HER-
2 gene of 48 CRC patient-derived xenografts (PDX) 
samples that were cetuximab-resistant and wild-type (WT) 
for KRAS, NRAS, BRAF, and PIK3CA (quadruple WT): 
four of these PDXs had HER-2 mutations. The effect of 
HER2-targeted therapies on two of these PDXs was 
assessed: single agent HER2-targeted therapy (with either 
trastuzumab, neratinib, or lapatinib) delayed the growth 
of these PDXs, while dual HER2-targeted therapy (with 
either trastuzumab plus neratinib or trastuzumab plus 
lapatinib) produced durable tumor regression [83].
Leto and coll. investigated the underlying 
cooperative mechanisms of co-targeting HER-2 with 
a monoclonal antibody and a small molecule. They 
evaluated the phosphorylation/activation of HER-2, 
HER-3, EGFR (HERs) and downstream transducers 
in HER2-overexpressing colorectal and gastric cancer 
cell lines; in addition, the in vivo outcome of antibody-
mediated HER-2 blockade with trastuzumab, reversible 
HER2-inhibition by lapatinib, and irreversible HER2-
inhibition by afatinib inpatient-derived tumorgrafts and 
cell-line xenografts was also assessed. The results of the 
study showed that trastuzumab monotherapy reduced 
HER-3 phosphorylation, with minor consequences on 
downstream transducers, while lapatinib acutely inhibited 
all HER receptors and effectors but led to delayed 
re-phosphorylation of HER-3 and EGFR and partial 
restoration of ERK and AKT activity. When combined 
with lapatinib, trastuzumab prevented HER3/EGFR 
reactivation and caused prolonged inhibition of ERK/
AKT. Interestingly, afatinib alone was also very effective 
in counteracting the reinstatement of HER-3, EGFR, and 
downstream signaling activation. In vivo, the combination 
of trastuzumab and lapatinib or single-agent afatinib 
resulted in evident tumor shrinkage. Taken together, these 
findings showed that only prolonged inhibition of HER-3 
and EGFR, achievable by dual blockade with trastuzumab 
and lapatinib or irreversible HER-2 inhibition by afatinib, 
led to regression of HER2-amplified gastrointestinal 
carcinomas [84]. These preclinical findings should be 
tested in clinical trials in order to validate the potential 
role of HER-2 as a target [85].
Whether HER-2 amplification is associated with 
specific clinico-pathological characteristics of CRC 
has also been studied. In a recent report, no association 
between HER-2 overexpression and gender, age, tumor 
site, size, depth of invasion, lymph node metastases 
or distant metastases was observed. In addition, no 
significant survival differences between tumors with 
or without HER-2 amplification were noted [75]. In 
other case series, HER-2 overexpression was not shown 
to be more frequently associated with microsatellite 
instability (MSI) or infiltrative tumor border, invasion 
depth, lymph node metastasis, distant metastasis, and 
perineural invasion. Both HER-2 overexpression and 
HER-2 gene amplification, however, were associated with 
rectal tumor location [66]. Accordingly, Missiaglia et al. 
observed that distal carcinomas are more often HER-2 
amplified compared to proximal ones [86]. Concordance 
between primary tumor and distant metastases of HER-2 
positivity has also been investigated [67, 87]. As a matter 
of fact, Lee et al. assessed in both primary and distant 
lesion KRAS and HER-2 status of 94 consecutive CRC 
patients who underwent curative resection of the primary 
tumor and liver or lung metastases. HER-2 protein 
overexpression was assessed by IHC, with only 2.1% of 
cases overexpressed. HER-2 amplification was observed 
in 10.1% of combined primary tissue and metastases, 
suggesting high levels of concordance between 
primary disease and paired secondary lesions [67]. In a 
retrospective Italian study that enrolled 50 CRC patients 
neurosurgically resected for secondary brain lesions, the 
overall HER-2 positivity of brain metastases was 12%, 
and a concordance rate of 89% between primary tumor 
and distant lesion was reported [87]. In line with these 
results, a high concordance between the primary tumor 
and liver metastasis was also described in another study 
[88] thus suggesting that metastatic lesions may also be 
suitable for anti-HER-2 therapy.
The predictive role of HER-2 in CRC has been 
recently unveiled. Unlike cetuximab and panitumumab, 
treatment response to trastuzumab highly depends on 
HER-2 protein overexpression and gene amplification. 
Since approximately 5% of all CRC patients have 
membranous overexpression, HER-2 inhibitors were 
supposed to be effective only in a small subgroup of 
patients, who should be therefore selected based on of 
their HER-2 expression pattern. The definition of the role 
of anti-HER-2 treatment for metastatic CRC has not been 
straightforward with two pivotal clinical trials prematurely 
closed due to a slow accrual: the low incidence of HER-
2 overexpression was to blame for such failure [89, 90]. 
Moreover, a phase II study failed to show sufficient 
activity for the combination of capecitabine and lapatinib 
in patients with refractory intestinal adenocarcinoma [91], 
while preclinical synergy was demonstrated for the oral 
HER-2 inhibitor combined with panobinostat, a histone 
deacetylase inhibitor [75, 92]. Whether HER-2 inhibition 
could restore sensitivity to EGFR inhibitors was also 
studied. A phase I/II trial has been conducted to assess 
the efficacy and safety of cetuximab in combination with 
pertuzumab in patients with cetuximab-resistant metastatic 
CRC. Despite an encouraging RR, the study was 
prematurely stopped due to severe overlapping toxicities 
of the two compounds, which included severe skin rash, 
mucositis and diarrhea [93].
The HERACLES trial (HER2 Amplification for 
Colo-rectaL Cancer Enhanced Stratification) tested the 
combination of trastuzumab plus lapatinib or pertuzumab 
in metastatic HER2-amplified CRC patients. A validation 
study was conducted in order to develop a validated 
ERBB2 scoring system for colorectal cancer with the 
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aim of identifying ERBB2-positive patients suitable for 
enrollment in the HERACLES trial [94]. In both archival 
test cohort (n = 256) and in the validation cohort (n = 830) 
a 5% of KRAS wild-type pretreated CRC patients were 
found to be HER2-positive. In the phase II HERACLES 
trial, 23 heavily pretreated KRAS wild-type, HER2-
positive patients (IHC 3+ or 2+ and FISH positive with 
HER-2-to-CEP17 ratio >2), refractory to all standard 
agents including fluoropyrimidines, oxaliplatin, irinotecan, 
bevacizumab, and EGFR-inhibitors, were treated with 
trastuzumab and lapatinib. The primary trial endpoint was 
RECIST-determined objective RR.
Overall, 913 patients were screened, 44 were found 
to be HER2-positive and 23 were enrolled (2.3% of those 
screened). The Italian investigators observed 8 responses 
out of 23 treated patients (ORR 32%) and the trial met its 
primary endpoint before the enrollment was completed, 
with a median time to progression of 5.5 months (95%CI 
3.7-9.8) and some long-lasting responders. HERACLES, 
the first precision medicine trial with positive results 
in advanced CRC, proved that the combination of 
trastuzumab and lapatinib is clinically effective in HER2-
positive heavily pretreated metastatic CRC patients. As 
such, this combination needs to be further investigated in 
earlier treatment lines [95]. 
Finally, HER-2 can be immunogenic and generate 
antibodies and activation of T lymphocytes, suggesting that 
it can also be a target for T cell-directed immunotherapy 
[71]. Like in sarcomas, which are also tumors that express 
HER-2 at too low levels for HER-2 monoclonal antibodies 
to be effective, the role of immunotherapy with T cells 
genetically modified to express HER-2 may also be tested 
in metastatic CRC [96]; this might be an interesting option 
that could be considered for those metastatic CRC patients 
displaying cytoplasmic HER-2 overexpression [71].
Taken together, these pre-clinical and clinical data, 
pose HER-2 as an attractive object of interest, mainly from 
a therapeutic point of view, in the treatment of metastatic 
CRC. The assessment of HER-2 status may therefore be 
useful both as predictive factor of response to treatment 
with EGFR-inhibitors both as the main therapeutic target 
in a percentage, albeit small, of patients suffering from 
metastatic CRC. In this context, it would be useful to plan 
clinical trials testing the activity of anti-HER2 agents not 
only as drugs able to restore the sensitivity to EGFR-
inhibitors, but also in a first line setting. For these reasons, 
despite HER2-positivity is observed more often in RAS wt 
disease, it might be useful to assess the HER-2 status both 
since the diagnosis of metastatic CRC and subsequently 
during biopsy of a metastatic site.
CONCLUSIONS
Although palliative chemotherapy may improve both 
patient’s outcome and quality of life, its overall benefit 
is still limited. However, with the introduction of novel 
targeted therapies, the median survival of gastrointestinal 
malignancies is slowly but constantly improving, but 
a thorough understanding of CRC molecular biology is 
required to develop new targeted compounds.
Significant benefits have been observed with 
trastuzumab in HER2-positive tumors but the journey 
to a full implementation of anti-HER-2 therapy has 
just begun. Ongoing clinical trials are aiming at a 
better patient selection mainly according to the tumor 
molecular profile. Evidence that HER-2 overexpression 
drives progression and resistance to therapy in a limited 
subset of gastrointestinal cancers, thus becoming a valid 
drug target in this setting, has represented a major step 
forward in tailoring cancer therapy. However, anti-HER-2 
treatment, even when tested in a selected biomarker-
positive population, provides only modest survival gains 
[9, 95], given the inevitable development of acquired 
resistance. Intratumour heterogeneity, supporting clonal 
evolution under treatment pressure, is the main culprit for 
the emergence of resistance [97]. Additional oncogenic 
and epigenetic events have also been reported to confer 
resistance to HER-2 treatment in gastrointestinal cancers, 
suggesting that combination inhibitory strategies should 
be pursued to effectively prevent or delay the development 
of resistance [92]. Moreover, understanding secondary 
features that contribute to resistance, may allow the 
development of rational combination approaches 
to improve the efficacy of anti-HER-2 treatment in 
gastrointestinal cancers. To accomplish this, “liquid 
biopsies” allow a dynamic monitoring of clonal evolution, 
providing a valid tool to maximize anti-HER-2 treatment 
for gastrointestinal cancers [12].
This will ultimately help clinicians to administer 
the right treatment to the right patient increasing survival, 
decreasing side effects and finally improving quality of 
life.
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